tradingkey.logo

BUZZ-Tevogen Bio jumps on expanded Microsoft AI collaboration

ReutersJan 27, 2025 11:53 AM

Shares of drug developer Tevogen Bio TVGN.O rise ~48% to $2 premarket

On Friday, TVGN said it is expanding its partnership with Microsoft MSFT.O to use AI to improve its immunotherapy treatments

Co's proprietary tech, PredicTcell, will be developed on Microsoft's Azure cloud platform to identify precise T-cell targets - TVGN

TVGN said it is also using MSFT's AI tools and Azure cloud platform to proactively investigate potential treatments for human papillomavirus - viral infection that can cause genital warts and certain types of cancer

Last year, TVGN announced its partnership with Microsoft, and its shares surged to ~54%

TVGN fell 90.7% in 2024

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI